Brief: RenovoRx, Imugene Announce Collaboration To Deliver Oncolytic Virus Therapy
20/07/2023 13:19
July 20 (Reuters) - Imugene Ltd IMU.AX :
* RENOVORX AND IMUGENE ANNOUNCE COLLABORATION TO DELIVER
ONCOLYTIC
VIRUS THERAPY USING PROPRIETARY TRANS-ARTERIAL MICRO-PERFUSION
(TAMP™) PLATFORM
* RENOVORX INC- COLLABORATION WILL EXPLORE TRANS-ARTERIAL
DELIVERY
OF IMUGENE'S CF33 ONCOLYTIC VIRUS UTILIZING RENOVORX'S TAMP
THERAPY PLATFORM.
Source text for Eikon: ID:nBw8rk6tca
Further company coverage: IMU.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Imugene
See all newsAustralia's Imugene rises on fresh responses in blood cancer drug trial
Brief: Imugene Ltd Says Leslie Chong Resigns As CEO
Australia's Imugene loses most in over 8-years on discounted placement
Brief: Imugene To Raise A$11.12 Million Via Placement At A$0.095 Per Share
Brief: Imugene Requests Trading Halt Pending Proposed Capital Raising Announcement